UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2015
Commission File Number: 001-36596
___________________
TRILLIUM THERAPEUTICS INC.
(Translation of registrant's name into English)
96 Skyway Avenue
Toronto, Ontario M9W 4Y9
Canada
(Address of principal executive offices)
___________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)[ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)[ ]
DOCUMENTS FILED AS PART OF THIS FORM 6-K
See the Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Trillium Therapeutics Inc. | |
Date: December 3, 2015 | |
By: /s/ James Parsons | |
Name: James Parsons | |
Title: Chief Financial Officer |
2
EXHIBIT INDEX
Exhibit | Description |
99.1 | News Release dated December 3, 2015 |
FOR IMMEDIATE RELEASE | NASDAQ:TRIL |
TSX: TR |
TRILLIUM TO PROVIDE UPDATE ON CD47 IMMUNE CHECKPOINT
INHIBITOR PROGRAM AT THE 2015 AMERICAN SOCIETY OF
HEMATOLOGY ANNUAL MEETING
Toronto, Ontario, December 3, 2015 Trillium Therapeutics Inc. (Nasdaq:TRIL; TSX: TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor program targeting CD47 at the 57th Annual Meeting of the American Society of Hematology. Details of the poster presentation, entitled SIRPaFc, a CD47-Blocking Cancer Immunotherapeutic, Sensitizes Malignant B cells to Macrophage-Mediated Destruction, are listed below:
Date: Sunday December 6, 2015
Time: 6:00 pm 8:00 pm (EST)
Session: 201. Granulocytes, Monocytes and Macrophages: Poster II
Abstract #: 2191
Presenter: Dr. Natasja Nielsen Viller, Research
Scientist
Location: Hall A, Orange County Convention Center
The company will present data demonstrating that its SIRPaFc fusion protein, which targets the CD47 do not eat signal, triggers macrophage-mediated phagocytosis of a broad range of human B cell tumors and was effective at controlling the growth of aggressive B lymphoma xenografts in mice. Based on the supportive findings of these and other preclinical studies, Trillium is initiating a phase I dose-escalation study of SIRPaFc in patients with advanced lymphoma and other hematological cancers.
Patients with cancer clearly benefit from immune checkpoint inhibitors, commented Trilliums Chief Medical Officer, Dr. Eric Sievers. We hope to show that interrupting the CD47-SIRPa inhibitory synapse with our decoy receptor will have similarly transformative potential.
About Trillium Therapeutics:
Trillium Therapeutics
Inc. is an immuno-oncology company developing innovative therapies for the
treatment of cancer. The Companys lead program is a SIRPaFc antibody-like
fusion protein that blocks the activity of CD47, a molecule that is upregulated
on a wide variety of tumors. CD47 binds to SIRPa on macrophages and delivers a
do not eat signal that inhibits the ability of macrophages to phagocytose
(engulf and destroy) malignant cells.
For more information visit: www.trilliumtherapeutics.com
Caution Regarding Forward-Looking Information:
This
press release may contain forward-looking statements, which reflect Trilliums
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such risks
and uncertainties include but are not limited to the risk that the preclinical
testing of TTI-621 may not be predictive of the results or success of clinical
trials, and our expectations of the checkpoint inhibitor activity of TTI-621.
Investors should consult the companys quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on the risks
and uncertainties relating to the forward-looking statements and are cautioned
against placing undue reliance on forward-looking statements. Except as required
by applicable securities laws, Trillium undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Trillium Therapeutics Inc.
James Parsons
Chief Financial Officer
+1 416 595 0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com
-2-
A(K>^FKLCFMK[JN_/\BE;ZO=2:K]F91Y3.4V!<%1TZ^U-BT5[&Z%S<3(M
MO"P;=W/H,5HV]RE[;7,]G;A+A